BioNTech SE (BNTX) EV/EBITDA Ratio: N/A
The EV/EBITDA ratio for BioNTech SE (BNTX) is N/A as of Wednesday, June 10, 2026.
BNTX EV/EBITDA Ratio Chart
BNTX Average EV/EBITDA Ratio Chart
BNTX EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
51.40x
EV/EBITDA RATIO AVG 3Y
19.63x
EV/EBITDA RATIO AVG 5Y
20.05x
EV/EBITDA RATIO AVG 10Y
20.05x
EV/EBITDA RATIO AVG 15Y
20.05x
EV/EBITDA RATIO AVG 20Y
20.05x
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BNTX Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | $21.81B | N/A | 51.40x | 19.63x | 20.05x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 20.28x | 23.56x | 23.88x | 26.50x |
| Waters Corporation (WAT) | $23.83B | 38.03x | 21.59x | 21.24x | 21.45x |
| Moderna, Inc. (MRNA) | $18.40B | N/A | 12.39x | 25.27x | 25.27x |
| Hologic, Inc. (HOLX) | $16.97B | 17.28x | 15.01x | 15.35x | 12.41x |
| Veeva Systems Inc. (VEEV) | $26.73B | 25.37x | 43.29x | 56.90x | 62.37x |
| Biogen Inc. (BIIB) | $29.00B | 11.60x | 8.56x | 11.16x | 12.22x |
| DexCom, Inc. (DXCM) | $29.24B | 23.24x | 28.10x | 43.48x | 70.03x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 8.90x | 13.19x | 14.98x | 17.09x |
| Medline Inc. (MDLN) | $30.90B | 13.75x | 15.00x | 15.00x | 15.00x |
Understanding EV/EBITDA
Enterprise Value (EV) = Market Cap + Total Debt - Cash
EBITDA = Earnings Before Interest, Taxes, Depreciation & Amortization
EV/EBITDA is commonly used for comparing companies because:
- It accounts for debt levels (capital structure neutral)
- It removes effects of different depreciation policies
- It can be compared across countries with different tax rates
- It can remain available when net income is negative, if EBITDA is positive
BioNTech SE EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
BioNTech SE EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for BioNTech SE (BNTX)?
- The EV/EBITDA ratio for BNTX stock is N/A.
- What is the TTM average EV/EBITDA ratio for BioNTech SE (BNTX)?
- The TTM average EV/EBITDA ratio for BNTX stock is 51.40x.
- What is the 3Y average EV/EBITDA ratio for BioNTech SE (BNTX)?
- The 3Y average EV/EBITDA ratio for BNTX stock is 19.63x.
- What is the 5Y average EV/EBITDA ratio for BioNTech SE (BNTX)?
- The 5Y average EV/EBITDA ratio for BNTX stock is 20.05x.
- What is the 10Y average EV/EBITDA ratio for BioNTech SE (BNTX)?
- The 10Y average EV/EBITDA ratio for BNTX stock is 20.05x.
- What is the 15Y average EV/EBITDA ratio for BioNTech SE (BNTX)?
- The 15Y average EV/EBITDA ratio for BNTX stock is 20.05x.
- What is the 20Y average EV/EBITDA ratio for BioNTech SE (BNTX)?
- The 20Y average EV/EBITDA ratio for BNTX stock is 20.05x.
BioNTech SE EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2024-06-27 | 154.68x |
| 2024-06-26 | 162.72x |
| 2024-06-25 | 169.71x |
| 2024-06-24 | 178.08x |
| 2024-06-21 | 170.68x |
| 2024-06-20 | 175.34x |
| 2024-06-18 | 176.81x |
| 2024-06-17 | 184.96x |
| 2024-06-14 | 198.63x |
| 2024-06-13 | 213.36x |
| 2024-06-12 | 220.53x |
| 2024-06-11 | 223.88x |
| 2024-06-10 | 220.80x |
| 2024-06-07 | 229.66x |
| 2024-06-06 | 235.19x |
| 2024-06-05 | 237.78x |
| 2024-06-04 | 226.43x |
| 2024-06-03 | 239.17x |
| 2024-05-31 | 230.64x |
| 2024-05-30 | 223.69x |
| 2024-05-29 | 202.95x |
| 2024-05-28 | 206.22x |
| 2024-05-24 | 216.93x |
| 2024-05-23 | 224.63x |
| 2024-05-22 | 237.03x |
| 2024-05-21 | 198.60x |
| 2024-05-20 | 200.10x |
| 2024-05-17 | 193.11x |
| 2024-05-16 | 202.01x |
| 2024-05-15 | 199.08x |
| 2024-05-14 | 199.38x |
| 2024-05-13 | 201.04x |
| 2024-05-10 | 197.09x |
| 2024-05-09 | 198.56x |
| 2024-05-08 | 191.31x |
| 2024-05-07 | 194.12x |
| 2024-05-06 | 203.40x |
| 2024-05-03 | 201.04x |
| 2024-05-02 | 199.23x |
| 2024-05-01 | 190.63x |
| 2024-04-30 | 186.39x |
| 2024-04-29 | 183.12x |
| 2024-04-26 | 180.34x |
| 2024-04-25 | 178.46x |
| 2024-04-24 | 183.64x |
| 2024-04-23 | 185.15x |
| 2024-04-22 | 183.34x |
| 2024-04-19 | 178.83x |
| 2024-04-18 | 176.43x |
| 2024-04-17 | 177.29x |
| 2024-04-16 | 177.07x |
| 2024-04-15 | 182.89x |
| 2024-04-12 | 177.60x |
| 2024-04-11 | 179.59x |
| 2024-04-10 | 185.75x |
| 2024-04-09 | 191.01x |
| 2024-04-08 | 188.23x |
| 2024-04-05 | 192.77x |
| 2024-04-04 | 190.59x |
| 2024-04-03 | 193.75x |
| 2024-04-02 | 196.57x |
| 2024-04-01 | 202.54x |
| 2024-03-28 | 7.94x |
| 2024-03-27 | 8.09x |
| 2024-03-26 | 7.83x |
| 2024-03-25 | 8.09x |
| 2024-03-22 | 7.86x |
| 2024-03-21 | 7.89x |
| 2024-03-20 | 7.50x |
| 2024-03-19 | 8.32x |
| 2024-03-18 | 8.09x |
| 2024-03-15 | 7.99x |
| 2024-03-14 | 8.08x |
| 2024-03-13 | 8.28x |
| 2024-03-12 | 8.64x |
| 2024-03-11 | 8.75x |
| 2024-03-08 | 7.75x |
| 2024-03-07 | 7.71x |
| 2024-03-06 | 7.77x |
| 2024-03-05 | 7.60x |
| 2024-03-04 | 7.36x |
| 2024-03-01 | 7.68x |
| 2024-02-29 | 7.29x |
| 2024-02-28 | 7.78x |
| 2024-02-27 | 8.05x |
| 2024-02-26 | 8.20x |
| 2024-02-23 | 8.29x |
| 2024-02-22 | 8.21x |
| 2024-02-21 | 8.04x |
| 2024-02-20 | 7.74x |
| 2024-02-16 | 7.83x |
| 2024-02-15 | 8.08x |
| 2024-02-14 | 7.79x |
| 2024-02-13 | 7.61x |
| 2024-02-12 | 8.27x |
| 2024-02-09 | 8.12x |
| 2024-02-08 | 8.31x |
| 2024-02-07 | 8.50x |
| 2024-02-06 | 8.69x |
| 2024-02-05 | 8.16x |
| 2024-02-02 | 8.02x |
| 2024-02-01 | 8.40x |
| 2024-01-31 | 8.50x |
| 2024-01-30 | 8.49x |
| 2024-01-29 | 8.65x |
| 2024-01-26 | 8.45x |
| 2024-01-25 | 8.87x |
| 2024-01-24 | 9.27x |
| 2024-01-23 | 9.55x |
| 2024-01-22 | 9.45x |
| 2024-01-19 | 9.14x |
| 2024-01-18 | 9.00x |
| 2024-01-17 | 9.01x |
| 2024-01-16 | 9.40x |
| 2024-01-12 | 10.20x |
| 2024-01-11 | 10.22x |
| 2024-01-10 | 10.69x |
| 2024-01-09 | 11.23x |
| 2024-01-08 | 11.86x |
| 2024-01-05 | 11.82x |
| 2024-01-04 | 10.98x |
| 2024-01-03 | 11.50x |
| 2024-01-02 | 11.95x |
| 2023-12-29 | 2.72x |
| 2023-12-28 | 2.73x |
| 2023-12-27 | 2.84x |
| 2023-12-26 | 2.67x |
| 2023-12-22 | 2.71x |
| 2023-12-21 | 2.61x |
| 2023-12-20 | 2.56x |
| 2023-12-19 | 2.79x |
| 2023-12-18 | 2.61x |
| 2023-12-15 | 2.53x |
| 2023-12-14 | 2.63x |
| 2023-12-13 | 2.23x |
| 2023-12-12 | 2.32x |
| 2023-12-11 | 2.43x |
| 2023-12-08 | 2.60x |
| 2023-12-07 | 2.51x |
| 2023-12-06 | 2.48x |
| 2023-12-05 | 2.33x |
| 2023-12-04 | 2.39x |
| 2023-12-01 | 2.36x |
| 2023-11-30 | 2.42x |
| 2023-11-29 | 2.35x |
| 2023-11-28 | 2.30x |
| 2023-11-27 | 2.22x |
| 2023-11-24 | 2.33x |
| 2023-11-22 | 2.28x |
| 2023-11-21 | 2.23x |
| 2023-11-20 | 2.33x |
| 2023-11-17 | 2.36x |
| 2023-11-16 | 2.38x |
| 2023-11-15 | 2.44x |
| 2023-11-14 | 2.44x |
| 2023-11-13 | 2.28x |
| 2023-11-10 | 2.37x |
| 2023-11-09 | 2.36x |
| 2023-11-08 | 2.38x |
| 2023-11-07 | 2.54x |
| 2023-11-06 | 2.38x |
| 2023-11-03 | 2.15x |
| 2023-11-02 | 1.96x |
| 2023-11-01 | 2.02x |
| 2023-10-31 | 2.02x |
| 2023-10-30 | 2.01x |
| 2023-10-27 | 1.89x |
| 2023-10-26 | 2.20x |
| 2023-10-25 | 2.12x |
| 2023-10-24 | 2.15x |
| 2023-10-23 | 1.96x |
| 2023-10-20 | 1.87x |
| 2023-10-19 | 2.01x |
| 2023-10-18 | 2.07x |
| 2023-10-17 | 2.20x |
| 2023-10-16 | 2.22x |
| 2023-10-13 | 2.61x |
| 2023-10-12 | 2.91x |
| 2023-10-11 | 3.03x |
| 2023-10-10 | 3.05x |
| 2023-10-09 | 2.94x |
| 2023-10-06 | 3.05x |
| 2023-10-05 | 2.97x |
| 2023-10-04 | 2.99x |
| 2023-10-03 | 2.94x |
| 2023-10-02 | 3.14x |
| 2023-09-29 | 2.90x |
| 2023-09-28 | 1.47x |
| 2023-09-27 | 1.51x |
| 2023-09-26 | 1.46x |
| 2023-09-25 | 1.51x |
| 2023-09-22 | 1.57x |
| 2023-09-21 | 1.64x |
| 2023-09-20 | 1.72x |
| 2023-09-19 | 1.79x |
| 2023-09-18 | 1.74x |
| 2023-09-15 | 1.89x |
| 2023-09-14 | 1.92x |
| 2023-09-13 | 1.90x |
| 2023-09-12 | 1.99x |
| 2023-09-11 | 2.08x |
| 2023-09-08 | 2.16x |
| 2023-09-07 | 2.15x |
| 2023-09-06 | 2.16x |
| 2023-09-05 | 2.23x |
| 2023-09-01 | 2.22x |
| 2023-08-31 | 2.19x |
| 2023-08-30 | 2.35x |
| 2023-08-29 | 2.25x |
| 2023-08-28 | 2.18x |
| 2023-08-25 | 2.07x |
| 2023-08-24 | 2.12x |
| 2023-08-23 | 2.27x |
| 2023-08-22 | 2.30x |
| 2023-08-21 | 2.06x |
| 2023-08-18 | 1.79x |
| 2023-08-17 | 1.90x |
| 2023-08-16 | 1.70x |
| 2023-08-15 | 1.61x |
| 2023-08-14 | 1.68x |
| 2023-08-11 | 1.66x |
| 2023-08-10 | 1.60x |
| 2023-08-09 | 1.64x |
| 2023-08-08 | 1.46x |
| 2023-08-07 | 1.34x |
| 2023-08-04 | 1.64x |
| 2023-08-03 | 1.65x |
| 2023-08-02 | 1.58x |
| 2023-08-01 | 1.67x |
| 2023-07-31 | 1.73x |
| 2023-07-28 | 1.68x |
| 2023-07-27 | 1.58x |
| 2023-07-26 | 1.60x |
| 2023-07-25 | 1.65x |
| 2023-07-24 | 1.66x |
| 2023-07-21 | 1.72x |
| 2023-07-20 | 1.69x |
| 2023-07-19 | 1.74x |
| 2023-07-18 | 1.70x |
| 2023-07-17 | 1.67x |
| 2023-07-14 | 1.71x |
| 2023-07-13 | 1.76x |
| 2023-07-12 | 1.74x |
| 2023-07-11 | 1.69x |
| 2023-07-10 | 1.68x |
| 2023-07-07 | 1.65x |
| 2023-07-06 | 1.61x |
| 2023-07-05 | 1.74x |
| 2023-07-03 | 1.69x |
| 2023-06-30 | 1.70x |
| 2023-06-29 | 1.66x |
| 2023-06-28 | 1.32x |
| 2023-06-27 | 1.30x |
| 2023-06-26 | 1.32x |
| 2023-06-23 | 1.33x |
| 2023-06-22 | 1.33x |
| 2023-06-21 | 1.34x |
| 2023-06-20 | 1.40x |
| 2023-06-16 | 1.47x |
| 2023-06-15 | 1.49x |
Showing the most recent 260 of 816 data points. The chart above shows the full history.
Related Metrics
About BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin